Clinical Trials Logo

Oropharyngeal Cancer clinical trials

View clinical trials related to Oropharyngeal Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06446713 Not yet recruiting - Clinical trials for Head and Neck Cancer

PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer

PIRATES
Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

In this study the safety & feasibility of image-guided mid-treatment hyper-fractioned dose-escalation with proton therapy will be assessed for the treatment of locally advanced HPV-negative squamous cell oropharyngeal cancer

NCT ID: NCT06445114 Not yet recruiting - Carcinoma Clinical Trials

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

NCT ID: NCT05582590 Not yet recruiting - Clinical trials for Head and Neck Cancer

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

Start date: March 31, 2025
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers. Patients must have received at least one prior standard treatment regimen consisting of systemic immunotherapy and/or chemotherapy. The investigative agent is an autologous adoptive T-cell product derived from the patient's endogenous cytolytic T cells that are directed toward HPV-16 E6/E7, HPV-18 E6/E7 antigens, and a tumor-associated antigen (Survivin) by ex vivo exposure to an artificial antigen presenting cell to which HLA-A2 antigen-peptides have been fit within the pocket of an MHC class 1 molecule. Patients must express HLA-A*0201.

NCT ID: NCT03935672 Not yet recruiting - Clinical trials for Oropharyngeal Cancer

PEARL PET-based Adaptive Radiotherapy Clinical Trial

PEARL
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The PEARL study will recruit approximately 50 patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) who are about to undergo primary treatment with concurrent chemo-radiation from South Wales (Velindre Cancer Centre and Singleton Hospital, Swansea) and Bristol. The main aim is to see whether it is feasible to preform a positron emission tomography-computed tomography (PET-CT) scan after 2 weeks of radiotherapy and re-plan the radiotherapy based on this PET-CT scan, to re-distribute the dose of radiotherapy being delivered, so that a smaller area of normal tissues in the mouth and throat are treated to a high dose of radiotherapy.